Document Ymo1nYvk7VGBrMq81RZvNRz0

ror I<. Sent: Wednesday, May 3, 2023 3:44 PM To: ECHA EO <cexecutive-director@echa.europa.eu> ccf ia.eu> a >; nl aspenpharma.com; Subject: EFPI&A EFCG Outreach on PFAS Restriction Dear Ms McGuinness `With this | amwritingto you in my capacity as a chemical expert within EFPIA (European FEeCdHeAr.ation of Pharmaceutical Industries Association), an accredited stakeholder observer at On Tuesday 25 April EFPIA and EFCG (European Fine Chemicals Group) had good engagementvith representatives from the competent authoritiesofthe Netherlands, Ndiosrcwuasys,ioansn,diSt wbeedceanmeonaptphaerePnFtAtShartetsthreircetiaornecosnosmuletaqtuieosntipornoscetshsa.t aHroewbeevsetra,ndsuwreinrgedoubry ECHA personnel. PFAS type materials are used throughout the supply chainof medicinal products and in the plant and equipment within pharmaceutical manufacturing facilities. To help the ECHA Committees, we would like clarificationon the environmental and socio-economic impact assessment that our sector needs to provide during the public consultation. Given the tight time frame that is involved, we believe it would be better if our discussions occocuulrd aisnspiestrswoitnhaanrdrawinlglitnrgavaelmetoetHienlsgiwnikit,hotrhwehreerleevvaenrt iEsCcoHnAvepneiresnot.nnTeoltithwaotuelxdtebnetmfuycohu appreciated. Itis recognisedthatthis is consideration given to this arevqeureystb.usy timeforyou, and we greatly appreciate any Kind regards, European Federation of Pharmaceutical Industries and Associations Leopold Plaza Building Rue du Troe 108. 8-1050 Brussels (Belgium) Tel: +353 0) 86 152J (mobile) Email: efpia.cu wwefpia.ey